Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability Study of DFD-29 vs Solodyn in Healthy Adults
NCT05452785Phase 1Completed
- Sponsor
- Journey Medical Corporation
- Start
- May 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of minocycline hydrochloride modified release (DFD-29) in rosacea (3 arms), sponsored by Journey Medical Corporation. Primary endpoints: Peak Plasma Concentration and Area Under the Curve from time 0 to infinity. Started May 2022; status: completed.
02
Drugs
minocycline hydrochloride modified release (DFD-29)
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT05452785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05452785.